(lp0
S'Repros Therapeutics Inc. RPRX  Wall Street Journal - Feb 12, 2011 Repros Therapeutics Inc. RPRX . search. View All companies. 12:59 PM EDT 03/13/17. $1.26 USD; 0.04 3.28%.'
p1
aS"Why Repros Therapeutics, Inc. Shares Are Soaring Motley Fool - Apr 2, 2015 Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis."
p2
aS'Repros Announces New CEO GlobeNewswire  - Feb 2, 2017 THE WOODLANDS, Texas, Feb. 02, 2017  -- Repros Therapeutics Inc.  today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors to&nbsp;...'
p3
aS"Repros Therapeutics Inc: Analysts See Substantial Upside Ahead of Androxal ... Smarter Analyst - May 29, 2015 Equity analysts have recently weighed in with favorable reports on Repros Therapeutics Inc , as the company's Androxal AdCom meeting and PDUFA preparations are in high gear."
p4
aS"Stock Update : Repros Therapeutics Inc Provides Phase 2 Results ... Smarter Analyst - Sep 7, 2016 Repros Therapeutics Inc  provided the results of the first course of treatment from Repros' ongoing study of Proellex for the treatment of premenopausal women with confirmed symptomatic endometriosis.Repros' Proellex successful in mid-stage endometriosis study; shares ahead 42 ... - Seeking Alpha"
p5
aS'Is It All Over For Repros Therapeutics? Seeking Alpha - Nov 23, 2015 Repros Therapeutics  and its investors received a major blow when FDA cancelled the advisory committee meeting scheduled for November 3, 2015 to decide the approval of Androxal  for secondary hypogonadism.'
p6
aS"Piper Jaffray Slashes Price Target for Repros Therapeutics Inc on Back of ... Smarter Analyst - Oct 29, 2015 In a research report published Thursday, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on shares of Repros Therapeutics Inc , while reducing the price target to $2.00 , following today's news that the FDA&nbsp;..."
p7
aS'Repros Therapeutics Inc Risk Points versus Health Care CML News - Mar 13, 2017 This is a scatter plot analysis of the critical risk points from the option market for Repros Therapeutics Inc  compared to its own past and the Health Care ETF.Repros Therapeutics Inc.  Q4 Earnings: Investors should not be expecting ... - Post AnalystRepros Therapeutics Inc  Scheduled to Post Earnings on Monday - The Cerbat Gem'
p8
aS'Repros Therapeutics Inc  Appoints New CEO StockNewsUnion - Mar 15, 2017 Repros Therapeutics Inc  reported that Joseph S. Podolski is resigning from his role of President, CEO, and Board-member to pursue other interests.'
p9
aS'Now May Be The Time To Buy Repros Therapeutics Seeking Alpha - Jan 3, 2015 Repros is a development stage biopharmaceutical company developing candidates for hormonal and reproductive system disorders.'
p10
a.